This is the Technical Web Site of ELISHA Systems Ltd.
ELISHA was the acronym of the EU project funded under the Nanotechnology Theme of Framework 6. The project was completed on 30th June 2007 and the technology is being commercialised by ELISHA Systems Ltd., a new SME based in the UK.
ELISHA Systems Ltd has new IP to construct biosensors based on conserved scaffold proteins and peptides. Initial examples have been demonstrated on Affimers, the peptide aptamer reagents supplied by Avacta plc. Biosensors to ANP (atrial natriuretic peptide) and LOX1 ( Lectin-like oxidized low-density lipoprotein (LDL) receptor-1) have been demonstrated to date. The new IP for biosensor manufacture has been found to produce more consistent and reliable impedance based biosensors.
More information in 'Latest News' below.
Main Contacts for ELISHA Systems Ltd:
Dr Tim Gibson Telephone 07968 162224
Duncan Sharp Telephone 0113 343 1435
416 Aberford Road
Company number 6142403
ELISHA Systems Ltd is developing Biochips and Point-of-Care Instrumentation based on the ELISHA immunosensor technology.
Since 2008, ELISHA Systems Ltd has been developing the ELISHA technology to be commercially viable. The basic technology comprises disposable single measurement biochips and an electrochemical reader that is being designed to be a Point-of-Care device.
Biochips can be configured in different ways:
1) Single analyte configuration – using 2 working electrodes to generate the specific signal and to correct for non-specific binding
2) Multiple analyte configuration – using multiple working electrodes to detect a number of target analytes from a single sample.
The analytical sequence to measure target analytes is essentially the same for each type of biochip.
Add sample to biochip – incubate for several minutes – read concentration.
The incubation time depends on the target and concentration range of the target analyte, but it is of the order of 5 to 20 minutes for most target analytes measured to date.
The development has demonstrated the feasibility of the antibody based biochips to detect many more analytes in a wide range of sample matrices. Some examples are given below.
ANALYTE MATRIX SENSITIVITY
Meningococcus Whole human blood 10 cells in 100µl blood
Myoglobin Human serum 10 picogrammes per ml
Fluoroquinoline antibiotics Bovine milk 1 nanogramme per ml
MRSA PBS / non-ionic detergent 10 cells per ml
To date most protein and carbohydrate biomarkers are quantifiable down to picogramme per ml levels in 20 minutes. Most bacterial samples seem to have a detection limit of 10 cells per ml or 10 cells per sample (e.g. for the miningococcus example, 100µl of whole blood containing 100cells per ml gave a consistently measurable response). Recently viruses have been detected and quantified directly using a virus antibody. In addition target analytes have been detected and quantified in neat human saliva and neat human urine working with third party clients.
ELISHA Systems Ltd has World-wide patent protection in the area of AC Impedance interrogation of protein biochips and has IP in an alternative electrochemical detection technique developed in the ELISHA project.
ELISHA Systems Ltd is looking to discuss potential collaborations with interested third parties who have analyte panels they would like to transfer onto the ELISHA platform. Please contact Dr Tim Gibson or Dr Graham Johnson using the contact details above.
New IP for Biosensor manufacture
Elisha Systems Ltd has new IP in the area of biosensor manufacture that produces consistent and reliable impedance based biosensors.
Biosensor World Congress Presentation
Labeless AC Impedance Based Biosensors:Commercial Reality or an Impossible Goal?
ELISHA Systems Ltd to present results for MRSA detection at the World Congress on Biosensors 2014
Specific detection of MRSA using a novel phage lysin mediated biosensor has been successfully demonstrated and the TSB sponsored project PROMPT-Plus is proceeding to trial the biosensors